NasdaqCM - Delayed Quote USD
Cue Biopharma, Inc. (CUE)
0.6410
+0.0109
+(1.73%)
At close: June 6 at 4:00:01 PM EDT
0.6700
+0.03
+(4.52%)
After hours: June 6 at 5:51:24 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.13 | -0.13 | -0.55 | -0.56 |
| Low Estimate | -0.13 | -0.13 | -0.55 | -0.56 |
| High Estimate | -0.13 | -0.13 | -0.55 | -0.56 |
| Year Ago EPS | -0.2 | -0.17 | -0.72 | -0.55 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 2M | 2M | 6.4M | 10M |
| Low Estimate | 2M | 2M | 6.4M | 10M |
| High Estimate | 2M | 2M | 6.4M | 10M |
| Year Ago Sales | 2.66M | 3.34M | 9.29M | 6.4M |
| Sales Growth (year/est) | -24.76% | -40.05% | -31.09% | 56.25% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.28 | -0.19 | -0.14 | -0.15 |
| EPS Actual | -0.2 | -0.17 | -0.13 | -0.17 |
| Difference | 0.08 | 0.02 | 0.02 | -0.02 |
| Surprise % | 28.57% | 10.03% | 11.72% | -10.87% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.13 | -0.13 | -0.55 | -0.56 |
| 7 Days Ago | -0.14 | -0.13 | -0.57 | -0.61 |
| 30 Days Ago | -0.14 | -0.13 | -0.57 | -0.61 |
| 60 Days Ago | -0.14 | -0.14 | -0.57 | -0.46 |
| 90 Days Ago | -0.14 | -0.14 | -0.57 | -0.46 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | 1 | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CUE | 35.00% | 23.95% | 24.00% | -1.82% |
| S&P 500 | 13.13% | 2.46% | 7.55% | 14.08% |
Upgrades & Downgrades
| Reiterates | Citizens Capital Markets: Market Outperform to Market Outperform | 4/2/2025 |
| Maintains | Stifel: Buy to Buy | 8/20/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 7/26/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 7/26/2024 |
| Maintains | Stifel: Buy to Buy | 4/9/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/9/2024 |
Related Tickers
EXOZ eXoZymes, Inc.
13.44
-1.93%
APTOF Aptose Biosciences Inc.
1.7400
-1.14%
RNTX Rein Therapeutics Inc.
2.0000
+2.56%
ACTU Actuate Therapeutics, Inc. Common stock
8.96
-1.43%
CAMP CAMP4 THERAPEUTICS CORPORATION
1.9200
+3.23%
ARTL Artelo Biosciences, Inc.
1.1200
+1.82%
RNXT RenovoRx, Inc.
1.3900
-0.71%
PHRRF PharmaTher Holdings Ltd.
0.1550
+3.33%
VOR Vor Biopharma Inc.
0.2238
+0.09%
GRI GRI Bio, Inc.
1.3800
-3.50%